Zelos Therapeutics Initiates Dosing in a Phase 1 Clinical Study of Nasal Spray Teriparatide

WEST CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Zelos Therapeutics, Inc. has initiated dosing in a seven day clinical study of a nasal spray formulation of ZT-034 (teriparatide) that is being developed in collaboration with development partner Aegis Therapeutics, LLC. Nasal spray ZT-034 is being developed as an alternative to Eli Lilly and Company’s Forteo (teriparatide [rDNA origin]) which generated approximately $800M in annual sales in 2009 for the treatment of osteoporosis and is administered by daily injection. Non-injectable formulations such as nasal spray ZT-034 could expand the market for parathyroid hormone (PTH) analogs to considerably more than $1 billion. The study design will include a Forteo treatment arm to provide an initial comparison with the marketed product.